LDP 392

Drug Profile

LDP 392

Alternative Names: CMI 392

Latest Information Update: 07 May 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals; University of Virginia
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Asthma; Atopic dermatitis; Psoriasis; Skin disorders

Most Recent Events

  • 22 Oct 2003 No development reported - Phase-II for Atopic dermatitis in USA (Topical)
  • 22 Oct 2003 No development reported - Phase-II for Psoriasis in USA (Topical)
  • 22 Oct 2003 No development reported - Preclinical for Adult respiratory distress syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top